ORKA NASDAQ
Oruka Therapeutics, Inc.
1W: +21.1%
1M: +13.8%
3M: +8.8%
YTD: +238.9%
1Y: +251.6%
3Y: +631.4%
5Y: +441.9%
$95.81
+5.48 (+6.07%)
Weekly Expected Move ±6.7%
$69
$75
$80
$86
$91
Credit Risk of going bust: lower than 89% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Oruka Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $6.34B.
Distance to default 13.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $669K (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 50.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down more than 99.9%), Oruka Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.5M against a stock market value of $6.34B.
Distance to default 13.34 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $669K (short-term plus half of long-term), stock volatility 67.3%; Altman Z'' 50.48. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.72
Bullish
4 bullish
1 neutral
0 bearish
Articles (24h)
5
Hourly Sentiment (24h)
0.52
Bullish
15 bullish
11 neutral
0 bearish
Articles (7d)
26
Daily Sentiment (7 Days)
Articles (100)
Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results - Yahoo Finance
Oruka Therapeutics Stock Gets A Lift From Psoriasis Trial Results
Oruka Therapeutics, Inc. - Common Stock (ORKA) Stock Price, News, Quote & History - FinancialContent
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study
Oruka’s ORKA-001 Delivers 61% Complete Skin Clearance in Phase IIb Psoriasis Study - Yahoo Finance
ORKA Stock Grinds Higher As Cash War Chest Fuels Speculation - Timothy Sykes
ORKA Stock Grinds Higher As Cash War Chest Draws Trader Focus - StocksToTrade
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift” - Yahoo Finance
Oruka Therapeutics Soars 12% as Psoriasis Drug Clears Skin in 61% of High-Dose Patients: “A Paradigm Shift”
Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis - Slideshow (NASDAQ:ORKA) 2026-10-26 - Seeking Alpha
Oruka Therapeutics Stock Soars - Here's Why - Oruka Therapeutics (NASDAQ:ORKA) - Benzinga
Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months
Oruka’s Psoriasis Treatment Could Generate $7B In Peak Sales, Says Guggenheim – ORKA Stock Heads For Best Day In Over 4 Months - Stocktwits
In a psoriasis trial, 61% had clear skin after 16 weeks; placebo did not. - Stock Titan
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis
Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis - Yahoo Finance
ORKA Mar 2027 145.000 put (ORKA270319P00145000) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
Oruka Therapeutics, Inc. Estimates – NASDAQ:ORKA - TradingView
Oruka Therapeutics, Inc. (ORKA) stock price, news, quote and history - Yahoo Finance UK
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026
Results from a psoriasis treatment study are due Monday. - Stock Titan
Oruka Therapeutics, Inc. (ORKA) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Halozyme, Up Nearly 90% This Year, Is Rivaling Merck And Hitting New Highs
ORKA Dec 2027 40.000 call (ORKA271217C00040000) Stock Historical Prices & Data - Yahoo! Finance Canada
Orca Energy Group Inc. (ORC-A.V) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oruka Therapeutics (ORKA) Stock May Be Trading On A Rich Premium To Book Value
These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Down 4.3% – Time to Sell?
Oruka Therapeutics (NASDAQ:ORKA) Stock: Insider Lawrence Otto Klein Sells 25,000 Shares
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data - Yahoo Finance
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
Oruka falls after updating mid-stage trial data for plaque psoriasis therapy
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
352,824 Shares in Oruka Therapeutics, Inc. $ORKA Bought by Bank of America Corp DE
Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 533 Shares
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference
Q3 EPS Estimate for Oruka Therapeutics Lowered by Analyst
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know
ORKA Stock Up More Than 60% in 3 Months: Here's What You Should Know - Yahoo Finance
BlackRock Inc. Purchases Shares of 4,990,181 Oruka Therapeutics, Inc. $ORKA
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month High – Here’s What Happened
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01
Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Moderate Buy” from Analysts
Atika Capital Management LLC Purchases New Position in Oruka Therapeutics, Inc. $ORKA
Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ORKA Stock Climbs As Traders Track Tight Range - StocksToTrade
ORKA Stock Grinds Higher As Traders Track Tight Range - timothysykes.com
ORKA Stock Climbs As Traders Track Strong Cash Runway - StocksToTrade
Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup - Quiver Quantitative
Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares - Investing.com
Discipline and Rules-Based Execution in ORKA Response - Stock Traders Daily
HMI Capital Pares Its Stake in AI Company nCino
How Investors May Respond To Oruka Therapeutics (ORKA) Russell Index Shift Toward Small-Cap Growth Benchmarks - simplywall.st
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News
H.C. Wainwright Keeps Buy Rating on Oruka (ORKA) After Apogee Acquisition News - Yahoo Finance
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean
Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mean - Yahoo Finance
ORKA Forecast — Price Target — Prediction for 2027 - TradingView
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?
Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors? - Yahoo Finance
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy - Investing.com
Insider Sell: Arjun Agarwal Sells Shares of Oruka Therapeutics I - GuruFocus
Oruka Therapeutics SVP Arjun Agarwal sells $128,468 in ORKA stock By Investing.com - Investing.com Australia
Oruka Therapeutics (ORKA) SVP sells 1,587 shares under 10b5-1 plan - Stock Titan
ORKA Stock Powers Higher As Traders Focus On Cash Runway - timothysykes.com
ORKA Stock Rips Higher As Bulls Press Momentum - StocksToTrade
ORKA Stock Extends Run As Bulls Press Momentum - timothysykes.com
ORKA Stock Extends Run As Bulls Defend Fresh Highs - StocksToTrade
ORKA Stock Climbs As Momentum Traders Lock In On Breakout - timothysykes.com
$ORKA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
ORKA Stock Climbs As Momentum Traders Lock In On Breakout - timothysykes.com
ORKA Stock Powers Higher As Traders Focus On Cash Runway - timothysykes.com
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
ORKA News | ORUKA THERAPEUTICS INC (NASDAQ:ORKA) - ChartMill
Oruka Therapeutics COO Laura Sandler sells $41,814 in ORKA shares - Investing.com
Oruka Therapeutics CEO Lawrence Klein sells $120,494 in stock - Investing.com
Oruka Therapeutics (ORKA) SVP exercises options, sells shares to cover tax obligations - Stock Titan
Oruka Therapeutics (ORKA) CMO sells shares and exercises stock options - Stock Titan
Oruka Therapeutics (ORKA) CEO has 1,729 shares sold for RSU tax withholding - Stock Titan
Oruka Therapeutics (ORKA) COO sells 600 shares to cover taxes - Stock Titan
Oruka Therapeutics (ORKA) counsel sells 733 shares in tax sell-to-cover - Stock Titan
Oruka’s Expanded IL-23 Rights Reshape Pipeline Options And Partner Potential - simplywall.st
Oruka Therapeutics (ORKA) Stock Valuation After A 147% Year-To-Date Surge And 8.7x P/B Rating - simplywall.st
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?
Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
ORKA (NASDAQ: ORKA) notice to sell 35,000 shares; insider sold 105,000 - Stock Titan